Choay, S.a.

Akzo Nobel N.v.

Sanofi Sa

Other

Sanofi

Akzo N.v.

Sanofi-aventis

Sanofi-synthelabo

Elf Sanofi

Sanofi (societe Anonyme)

Carbomimetics

Endotis Pharma

Catalent France Beinheim Sa

Azko Nobel

Snofi, S.a.

Maurice Petitou

Jean Choay

Jean-Claude Lormeau

Constant A Van Boeckel

Philippe Duchaussoy

Jean Marc Herbert

Pierre G Sinay

Pierre Savi

Jean-Claude Jacquinet

Constant Van Boeckel

Jean-Marc Herbert

Pierre Alexandre Driguez

Cornelia Dreef-Tromp

Johannes Basten

Jean Pascal Herault

Peter Grootenhuis

Constant Adriaan Anton Van Boeckel

Peter Diederik Grootenhuis

Tom Beetz

Ahmed El Hadri

Johannes Egbertus Maria Basten

Andr&eacute; Bernat

Guy Dubreucq

Francis Toulemonde

Guy F Jaurand

Pieter Westerduin

Mahmoud Nassr

Cornelia Maria Dreef-Tromp

Ronald Van Amsterdam

Guy Jaurand

Vanessa Nancy-Portebois

Guillaume Sabate

Nathalie Sicre

Julien Meissonnier

The invention concerns a pentasaccharide compound of formula (I)  The invention also concerns a pharmaceutical composition comprising the synthetic pentasaccharide compound of formula (I) and its salts. The invention further concerns these compounds for use as a medicament, and in particular intended to treat blood clotting disorders, to prevent ischaemia reperfusion injury associated with solid organ transplantation, or to reduce the risk of blood clotting in an extracorporeal blood circuit during cardiac surgery, extracorporeal membrane oxygenation, or during circulatory assistance such as artificial heart.

Synthetic pentasaccharides having short half-life and high activity

The present invention concerns a pharmaceutical formulation intended for oral administration containing a synthetic oligosaccharides containing one to 18 monosaccharide units and having a therapeutical activity or a pharmaceutically acceptable additions salt or solvate thereof wherein the formulation contains: a) the synthetic oligosaccharide (A) in an amount of up to 5% by weight of the total weight of the formulation, advantageously up to 1% by weight of the total weight of the formulation, b), a lipophilic phase (B) consisting of triglyceride of fatty acids in an amount of 50 to 80% by weight of the total weight of the formulation, advantageously of 50 to 70% by weight of the total weight of the formulation, c) at least one lipophilic surfactant (C) with HLB below 7 consisting of partial esters of polyol and fatty acids in an amount of 10 to 30% by weight of the total weight of the formulation, advantageously of 15 to 30% by weight of the total weight of the formulation, d) at least one hydrophilic surfactant (D) with HLB above 7 in an amount of up to 20% by weight of the total weight of the formulation, advantageously up to 15% by weight of the total weight of the formulation, e) optionally, at least one hydrophilic solvent (E) in an amount of up to 15% by weight of the total weight of the formulation, advantageously up to 10% by weight of the total weight of the formulation, (F) between 0 and 30% by weight of the total weight of the formulation of a chemical and/or physical stabilization agent (F), advantageously between 0 and 20% by weight of the total weight of the formulation, wherein when the formulation is in a form of a reverse emulsion or microemulsion and contains at least one hydrophilic solvent (E), the physical stabilization agent is present and is silicon dioxide.

Pharmaceutical oral dosage form containing a synthetic oligosaccharide

The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, Rand R, represent independently of one another a C-Calkoxy or and &#x2014;OSO; Rrepresents a C-Calkoxy or an &#x2014;OSO, or Rconstitutes a &#x2014;O&#x2014;CH&#x2014; bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines. 

Biotinylated hexadecasaccharides, preparation and use thereof

The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.

Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative

Synthetic polysaccharides are disclosed containing 8-24 monosaccharide units made up of a concatenation of disaccharides consisting of a uronic acid and a hexose, wherein the hydroxyl groups of the polysaccharides are etherified with a Calkyl group or esterified in the form of a sulpho group, each disaccharide being at least monoetherified; and salts thereof, are disclosed.

Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them

Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative

Pentasaccharides processes for their preparation and pharmaceutical compositions containing them

Compositions for treating arterial thrombosis and a factor Xa inhibitor

A synthetic polysaccharide including an antithrombin III binding domain consisting of a concatenation of five monosaccharides supporting a total of two carboxylic acid functions and at least four sulpho groups, said domain being directly bound at the non-reducing end by a thrombin binding domain including a concatenation of 10-25 monosaccharide units selected from hexoses, pentoses or deoxy sugars of which all the hydroxyl groups are etherified by a C alkyl group or esterified in the form of sulpho groups, as well as salts and particularly pharmaceutically acceptable salts thereof, are disclosed.

Synthetic polysaccharides, preparation method therefor and pharmaceutical compositions containing same

Novel synthetic polysaccharides for use in the treatment of pathologies associated with a coagulation dysfunction.

Synthetic polysaccharides, their method of production and pharmaceutical compositions containing same

The invention relates to a carbohydrate derivative having formula I

Carbohydrate derivatives

The invention relates to sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.

Sulfated glycosaminoglycanoid derivatives of the heparin sulfate type

The invention relates to a tuneable bisconjugate comprising two saccharides and a spacer, each saccharide being the same or different and comprising two to six monosaccharide units, at least one unit being uronic acid, characterized in that at least one of the saccharides per se has anti-thrombotic activity, and that the spacer connects at least one saccharide to the other through its non-reducing end, the chain length of the spacer being 20-120 atoms.

Bisconjugates comprising two saccharides and a spacer

Growing community of inventors

Paris, France

Maurice Petitou